The natural history of Human papillomavirus (HPV) in sub-Saharan Africa is not yet fully understood. As persistent HPV infection is a necessary factor in development of cervical cancer -a major health problem in sub-Saharan Africa -information about how HIV together with other risk factors interact with HPV acquisition and HPV persistence/clearance is warranted. Additionally, concern prevails about the quality of cervical cancer preventive strategies in sub-Saharan Africa. Against this background the project aims to provide a better understanding of the natural history of HPV with a view to HIV status, to measure the impact of a novel and simple screening method based on CareHPV testing and to assess how continuity of care among women who are tested HPV positive can be improved. The study will be linked up with the existing cervical cancer screening program at Ocean Road Cancer Institute (ORCI) and Kilimanjaro Christian Medical Centre (KCMC); and will include 4000 women who are attending screening service or HIV care and treatment. HPV acquisition and persistence/clearance patterns as well as the absolute risk of severe cervical precancerous lesions will be determined through a follow up study lasting 28 months. The test performance of CareHPV testing, liquid-based cytology and VIA will be described and the operating characteristics of the three screening methods will be assessed according to HIV status. Finally, the impact of a mobile phone intervention and a patient navigation model will be assessed and compared according to the proportion of HPV positive women who return for follow-up examinations. Additionally, the project will implement a research capacity building component focusing on transfer of knowledge and technology as well as training of PhD students. The activities will be carried out as five sub-studies: i) HPV acquisition pattern; ii) HPV persistence/clearance pattern; iii) Test performance of CareHPVtesting, liquid-based cytology and VIA; iv) Continuity of care among screened positive women and v) research capacity building as well as transfer of knowledge and technology
interview, and blood samples for HIV testing will be obtained. Before the initiation of the study, the staff in Tanzania will receive training in CareHPV testing. The CareHPV (including currently known HR-HPV types 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, 66, and 68) will be tested within 14 days in Tanzania. At the first follow-up, taking place 14 months after inclusion, a randomly selected sample of 500 women will be trained on self-collection of a cervical swab for HPV testing. Thereafter another cervical swab (ThinPrep) will be collected (on all study subjects in the 1 st follow-up) by a trained health provider. At the second follow-up, taking place 26 months after inclusion, a cervical swab (ThinPrep) will be obtained from each woman. Women who do not return to the clinic for first and second follow-up will be traced and visited at home and invited to attend the clinic for screening. If they do not wish to re-attend, they will be offered screening through a self-collected HPV sample. We anticipate a response rate in the 1 st follow-up at 90% and a response rate in the 2 nd follow-up at 80%. The anticipated follow-up rate is based on experiences from previous follow-up studies in Tanzania (7) . The study is grouped in five work packages according to the specific objectives:
Work package 1, Acquisition patterns of high-risk (HR) human papillomavirus (HPV) with a special view to HIV status:
Among women testing HR-HPV negative at baseline (Fig.2) , all women testing HIV positive (~190 from the screening clinic and 250 from HIV clinics = 440 in total) as well a random sample of 560 HPV negative/HIV negative women will be invited to a new gynecological examination after 14 months (1 st follow-up visit), where a health provider cervical swab (ThinPrep) sample on all women is taken. These samples will all be tested for HPV using HC2 and genotyping will be performed on the HPV positive samples. At the 2 nd follow-up visit (at 26 months) a health provider taken cervical swab (ThinPrep) will be obtained. All samples from the 2 nd follow-up will be sent to Denmark for establishment of a cytology diagnosis and the remaining material will be sent to Germany for HC2 testing and subsequent genotyping of the HPV positives. All cytology results and HPV results will be sent back to Tanzania. In case of a positive cytology (HSIL or worse) the woman will be called in and will be treated according to the cervical cancer screening standard of care methods in Tanzania. Based on the literature (8) we estimate an HPV acquisition rate among the initially HPV negative women at 1 st follow-up of around 10%, similarly an acquisition rare of 10% from the 1 st to the 2 nd follow-up. The association between HR-HPV acquisition and the women's age, lifestyle characteristics, reproductive history and HIV status will be assessed.
Work package 2, Persistence patterns of high-risk HPV types and absolute risk of severe cervical lesions focusing on the importance of HIV status: Persistence/clearance patterns of HR-HPV will be determined among all women who are HR-HPV positive at baseline (Fig. 2) (~700 from the screening clinic and 250 from the HIV clinic i.e. ~950 in total). They will be invited for follow-up examinations and tested for HR-HPV after 14 and 26 months (1 st and 2 nd followup visit). For this group of women also a self-collected cervical swab will be obtained at the 1 st follow-up in 500 randomly selected women. HPV genotyping will be performed among women who are HR-HPV positive during follow-up. Women who are persistently HPV positive for the same HPV type at enrolment and at 1 st follow-up will be called in for a cytological examination at the respective clinic. Also, in case of a positive cytology (HSIL or worse), the women will be called in for further follow-up. HR-HPV persistence/clearance patterns will be described in relation to the women's age, life style characteristics, reproductive history, HIV status and HPV genotype. We estimate a persistence rate of 40% after 14 months and of 20% after 26 months (9) . Due to the fact that a cytology diagnosis is obtained on all women at the 2 nd follow-up, we will also be able to look at the absolute risk of HSIL or worse in relation to both one-time HPV positivity, HPV persistence and according to HIV status.
Work package 3, Test performance of CareHPV testing, pap smear and VIA for detection of cervical precancerous lesions: As described above, all 4000 women enrolled will be screened by use of CareHPV testing, Pap smear (liquid-based cytology i.e. ThinPrep) and VIA at the study baseline, and the sensitivity and specificity of CareHPV testing and VIA will be estimated, and the positive and negative predictive values calculated. The operating characteristics of the two screening methods will be assessed according to HIV status. All VIA positive women will subsequently be treated in agreement with the cervical cancer screening standard of care methods in Tanzania. In case of a positive cytology that was not already identified through a positive VIA, the women will be called in for further follow-up. High-quality cervical liquid-based cytology and where possible also cervical biopsies will be used as Gold Standard. Based on the samples collected at the 1 st follow-up, the HPV results from the self-collected brush and the health provider collected brush will be compared.
Work package 4, Continuity of care among women who are tested are HPV positive -a comparison of two different interventions: Women who are tested HPV positive at enrolment will be randomized to either a patient navigation model or a cell phone model consisting of automated SMS messages. Patient navigation model: A trained community health worker will be identified as the woman's patient navigator. There will be established a one-to-one relationship between the patient navigator and the woman to address anticipated barriers such as communication difficulties and difficulties with arranging transportation. Cell phone model: HPV positive women will receive automatically generated SMS messages, which will convey HPV result, send appointment reminders and health information during the first 12-14 months follow-up period. After 20 months, the continuity of care, based on the number of HPV positive women who return for the 1 st follow-up examination after 14 months, will be compared. Additionally, the average time spent providing navigation from an HPV positive result is established to 12-14 months after and the associated cost will be calculated. Likewise, the price of establishing and maintaining the system generating the SMS reminders will be measured. The differences in total costs and re-attendance between patient navigation and SMS reminders will be calculated. Re-attendance will be defined as HPV positive woman who re-attend within 12-14 months after the HPV positive result is established. Finally, HPV positive women who do not re-attend for screening after 12-14 months will be traced and interviewed. A mixed method approach, relying on structured questionnaires, in-depth interview and key informant interviews will be used to describe perceived barriers for attending 12-14 months follow-up.
Work package 5, Health service capacity building for cervical cancer prevention: Health service capacity building will be performed at primary, secondary and tertiary level. At the primary and secondary levels, key barriers for optimal use of existing communication paths for ensuring continuity of care among women diagnosed with precancerous lesions will be identified through a register-based desk study. Based on the results, interview guides will be developed for in-depth interviews with health providers working at primary and secondary level and community representatives. The experiences from this assessment will be used to develop a training program in cervical cancer prevention and patient navigation that will include staff at primary and secondary health units together with community health workers in Dar es Salaam and Kilimanjaro Region. The trained community health worker will be employed as patient navigators. At tertiary level, the project will respond to the research needs set forth by ORCI and KCMC. Three PhD courses, one in Clinical Trials, one in Prevention and Control of Gynaecological Cancers and one in Policy Brief Writing will be offered at KCMC in alignment with the exiting BSU initiatives at KCMC. The PhD courses will be codeveloped and co-taught by Tanzanian and Danish researchers. At both ORCI and KCMC there is a need to strengthen the capacities of researchers to undertake in-country PhD training at an international level. To address this need, four PhD studies, three Tanzanian and one Danish (co funded by SDU), will be included in the project. The Tanzanian PhD students will be recruited through public announcement of the scholarships and competitive applications. Two of the Tanzanian PhD students will be enrolled at KCMC and one at ORCI. They will additionally conduct 3 months of academic work each year in Denmark. The project will be performed as a twinning arrangement where the Tanzanian and the Danish PhD students will work closely together. To increase the expertise within HPV epidemiology and HPV testing in Tanzania and thereby increase the sustainability of the project outcomes, a post-doctoral fellow, Crispin Kahesa(CK), who has obtained his PhD as part of our previous research (2-6, 9) and who is presently acting as national trainer for the cervical cancer prevention program in Tanzania, will be employed in the project. He will be visiting Institute of Medical Virology at Tuebingen University in Germany to get detailed knowledge about HPV testing and HPV analyses. In addition, to enhance local expertise in cervical cancer screening and HPV testing, a faculty exchange to the International Agency for Research on Cancer (IARC) in Lyon will also be arranged. Finally, to further upgrade CK's academic skills he will be involved as a co-supervisor of the two PhD projects focusing on Cervical Cancer Screening and Continuity of Care and write two independent papers based on the research findings.
Ethical research permissions will be obtained from the Ministry of Health in Tanzania and from local authorities in Dar es Salaam and Kilimanjaro. Ethical clearance will be obtained from the Ethical Review Board at KCMC and ORCI as well as from the Ethical Review Board of the National Institute of Medical Research. The project will follow the international ethical guidelines developed by CIOMS (Council for International Organization of Medical Sciences), placing particular emphasis on ensuring participant safety. Hence, women who have a positive cytology (HSIL or worse) will be called in and treated according to Tanzanian standard of care. Similarly, women who are persistently HPV positive will be traced, and liquid-based cytology samples will be obtained and analyzed. In case of a positive cytology result (HSIL or worse), the women will be offered colposcopy directed biopsies and treatment according to the cervical cancer screening national guidelines. Informed written consent will be obtained from research participants and confidentiality guaranteed. The trial will be registered at ClinicalTrials.gov and trial analyses and reports will be made in accordance with CONSORT requirements. It is an important part of the study that all women will have a cytology examination when they exit the study after 26 months and we will make sure that all women are cared for in the best possible way.
Expected outputs and outcomes
The project will produce 4 PhD theses, at least 14 scientific papers published in international, peer-reviewed journals, at least 5 articles published in popular journals/magazines, at least 6 conference papers (4 national and 2 international), and a minimum of 12 research updates and policy briefs.
The expected outcomes of the project are:
• New knowledge about the natural history of HPV infection and consequences of HPV infection among HIV positive and HIV negative women • New approaches in performing cervical cancer screening. On the basis of the research, possible improvements of the screening program will be identified, with a particular view to implementation of HPV testing and improved continuity of care • A cadre of health staff and community health workers who are trained in cervical cancer • control and prevention and who through an improved communication line will help facilitate on-going care and treatment to women who are screened positive • Improved capacities among researchers to conduct interdisciplinary and internationally • informed research on primary and secondary prevention of cervical cancer • Decreased mortality from cervical cancer due to detection of precancerous lesions and earlier detection of cervical cancer • Reduced poverty through enhancement of women's sexual and reproductive health. To a high degree cervical cancer is diagnosed in women at reproductive age and is thus leading to high numbers of premature deaths with substantial social and economic consequences at an individual level and in society. Prevention of cervical cancer will therefore have an impact on reduction of poverty and sustainable development in society.
Relevance
In Tanzania, cervical cancer is the commonest type of cancer in women, and that with the highest mortality rate.
Annually, approximately 7300 new cases are diagnosed and about 4200women die from cervical cancer (11) . Thus, cervical cancer is a public health problem that has enormous social and economic population impact as it often affects women at reproductive age (12) . To address this public health problem, the project will provide new and important information on the natural history of HPV and how it relates to HIV, information that will be of help in the development of more efficient vaccines and screening strategies that targets HIV positive and HIV negative women. The project also aims to evaluate CareHPV testing (a simple to do test) as a tool for cervical cancer screening and to examine how continuity of care of women who are screened positive can be improved by two simple low-cost interventions. The information generated from the project will help inform the future screening strategy in Tanzania as well as in other countries with high HIV prevalence. We will make it a priority that beside the publication of our results in scientific journals, we will communicate the results to decision makers, stakeholders and to the general population. The focus areas of our research, HPV, HIV and cervical cancer are well in line with the "Tanzanian National Health Research Policy" from 2013 that lists Communicable diseases, Non-communicable diseases and Reproductive health as top-three priority areas. Our research areas are also aligned with the Tanzanian Health Sector Strategic Plan III (HSSP III 2009-2015), supported by Danida, which also lists reproductive health and communicable and non-communicable diseases as priority areas. The project does also have relevance in relation to overall objectives and priorities of Danish development cooperation as expressed in The Right to a Better Life which states that "Denmark will be at the forefront of international efforts to promote sexual and reproductive health and rights, and in the fight against HIV/AIDS". Finally, through the linkage with KCMC, the activities are also in line with Danida priorities for research capacity building, since KCMC is one of the core institutions in the Building Stronger University (BSU) program.
Project plan
Since the project plan is complex and dynamic with interactions between multiple WPs, the key priorities will be to facilitate the necessary interactions between the WPs and to maintain the overall scientific direction over the life of the project. The project will start in January 2015 and end in December 2019. The existing ORCI and KCMC institutional bank accounts will be used for the project; and the existing financial and procurement regulations will be used for implementing the project in Tanzania. The main project milestones and timetable are shown on Fig. 3 . The detailed budget is attached in the main application and it shows how the resource allocation in the project will be distributed between the institutions involved over the project period.
Participants, organization and management Julius Mwaiselage is a medical doctor and epidemiologist and public health specialist. He is the Director of Cancer
Prevention Services at ORCI. He has 9 years experiences in cancer epidemiological research in Tanzania and has been involved in various collaborative research projects focusing on HPV prevalence, cervical cancer screening and HPV vaccine introduction in Tanzania. He has authored more than 20 scientific papers in peer-reviewed journals and supervised 3 PhD students and more than 15 master's students. Vibeke Rasch is a gynaecologist and professor in global reproductive health. She has almost20 years experiences in reproductive health research in Tanzania, has acted as principal responsible party in an enhancing research capacity building project in Vietnam and has been member of the BSU steering committee. She has authored more than 100 scientific publications and supervised 16 PhD students, more than half from sub-Saharan Africa and Asia. Susanne Krüger Kjaer is a medical doctor and professor of cancer epidemiology. Her main research areas are HPV and cancer and the importance of gene-environment interactions in cancer development with a focus on clinical utility and the translational aspect. She has authored more than 350 scientific papers, and she is the Danish primary investigator on the clinical, randomised trials of the efficacy of HPV vaccination. She has supervised more than 25 PhD students. Twalib Ngoma is a professor of oncology. He has more than 25 years of experience in teaching, clinical work and research related to cancer. He is the executive director of ORCI and the head of clinical oncology department of Muhimbili University College of Health and Allied Science. Rachel Manongi is Head of Community Medicine Department at KCMC, she has a record of community-based research with a special focus on HIV prevention and sustainable health promotion and has also been active in the establishment of a cervical cancer registry at KCMC. She has authored more than 40 papers in international journals.
The project builds on and extends existing collaboration between these Tanzanian and Danish researchers. The involved Danish researchers have solid experience in research capacity building in Tanzania and in HPV research and both have strong publication records. The proposed project will be undertaken in close coordination with the research capacity building activities conducted within the BSU initiative. The overall responsibility for the project lies with the main Tanzanian applicant. To facilitate cross-country project management, a Steering Board will be established between Tanzanian and Danish collaborators. A project management unit(PMU) will be established at ORCI. The PMU will consist of a project secretary and an accountant and will be responsible for day-to-day activities. To monitor the activities, a web-based project management tool will be established. The web tool will include detailed updated work plans linked to the work packages so partners can track project progress. Project documents will be available on the web-site. Members of the Steering Board will meet on a regular basis to ensure a continuous progress of the study. In addition, annual workshop meetings will be held with representatives from the partner institutions.
Project's international dimension
There is a great international interest in cervical cancer prevention focusing on different screening modalities, HPV testing and HPV vaccination, and it is one of the areas where substantial progress has been made in recent years and it is also one of the areas where research has the greatest translational potential. The suggested project relies heavily on collaboration between researchers in Tanzania, Denmark, Germany and France who have strong expertise in HPV epidemiology, HPV testing technology, cervical cancer screening approaches, and international health. Through this international collaboration, we will obtain a strong and valuable synergy. By means of this project there will be a great opportunity for transfer of knowledge and technology to Tanzania, which in a longer perspective may be further transferred to neighboring sub-Saharan African countries with similar high prevalence rates of HPV and HIV.
New knowledge
Virtually all cases of cervical cancers and high-grade precursor lesions are caused by a persistent infection with HPV(13). Although effective prophylactic vaccines against HPV have been developed, they are still relatively expensive and logistically demanding as they currently require a 3-dose regimen. Furthermore, they do not treat already existing HPV infections and related diseases. Several African cross-sectional studies of the prevalence of HPV have been performed, including our own from Tanzania where we found an HPV prevalence of 20.1% among 3700 women(2).
In the same study we found that 9.3% of the women were HIV positive. In contrast, only few prospective studies on HPV epidemiology have been conducted in Africa. Of these, some had a limited sample size (14) , some did only include HIV negative women(9) or exclusively used self-sampled cervical swabs (15) . In spite of the fact that cervical cancer is the most common malignancy among women in Sub-Saharan Africa(1), little is known about the distribution of HPV types, independent risk factors of incidence and patterns of persistence for different HPV types. Even though HPV16 has been found to be common in sub-Saharan African women, some studies have reported HPV52 and HPV58 to be more prevalent (2) . Data on which HPV types are more likely to persist in relation to HIV status are scarce, particularly in HIV positive individuals. Results from the proposed study will add important information to our knowledge about the natural history of HPV in an HIV high-risk area and will be helpful in tailoring screening programs to match the needs of HIV positive and HIV negative women.
The conventional cytology screening (Pap smear followed by colposcopically-directed biopsies) demands costly cytology laboratories with skilled and highly experienced personnel, and multiple visits at regular intervals are needed. Consequently, the Pap smear screening is neither sufficiently developed nor sustainable in less developed countries (16) . Therefore, cost effective methods such as VIA have been adopted in several countries for early detection of precancerous lesions. In 2002 cervical cancer screening based on VIA was implemented at ORCI and the program has subsequently been scaled up to cover other regions in Tanzania. However, several studies, including our own recent study, have found VIA to have a limited sensitivity(4). In contrast, HPV screening is appealing due to a higher sensitivity and a higher negative predictive value (17) . However, successful HPV screening in countries with limited resources requires a simple HPV test that will perform well also in remote areas and which is affordable. Finally, self-sampling will most likely be needed to make screening practical in some settings. . In relation to these issues, our study will contribute new knowledge which can immediately be used and implemented to the benefit of the women.
A successful programme for cervical cancer prevention requires function in its entirety. The programme should ensure high levels of screening coverage of the target population, offer high quality services, have good referral systems that guarantee patient follow-up and make certain that women receive appropriate treatment. Experiences from Tanzania mainland have documented that these preconditions are often not adhered to due to a poor functioning health system and as a consequence the screening results are often not conveyed and proper action not always taken. Currently, there is no mechanism in place in Tanzania to help women navigate between the potential barriers, which may be hindering factors for obtaining confirmatory diagnosis and adequate treatment of cervical precancerous lesions. Mobile Health, which implies the use of mobile communication devices for health care, is seen as a complementary strategy for strengthening health systems and the use of SMS has successfully been used to remind patients to take drugs and attend appointment e.g.in Kenya (18) . Similarly, members of our research team have documented the effect of SMS on antenatal care attendance and skilled delivery attendance in Tanzania (7).The Patient Navigation Model is an alternative approach to enhance continuity of care among underserved populations. The navigators can be trained community health workers or peer educators who provide support and guidance (19) . Patient navigation is used as a standard of care in most of Western oncological departments and has been proven to be successful in several studies e.g.: Cancer control among urban African American (20) and Breast cancer screening (21) . Understanding the acceptance of these two proposed models among Tanzanian women detected to have HPV will help health care professionals to develop more effective continuum of care programs by promoting attendance to HPV screening and follow-up of disease progression.
Publication and dissemination strategy
The research findings will be communicated via a project website, scientific paper in peer-reviewed journals and popular articles. Further to get maximum impact of the findings, a stakeholder workshop focusing on cervical cancer screening and continuity of care will be held at the beginning and at the end of the project. The invitees will include Women's groups representatives, civil society, health care providers, health sector officials and researchers. The workshop will involve stakeholders in the formulation of intervention strategies, which will enhance continuity of care among women who are screened positive. Further, at the end of the project period a policy brief workshop facilitated by a communication expert will be held and will result in the formulation of a policy brief that summarizes the research findings and provides recommendations to decision makers. The policy brief will be produced and shared at a national dissemination seminar where health policy makers, Danida representatives and other relevant stakeholder are invited.
Strategy for phasing out of the project
The project will be undertaken in cooperation with Ministry of Health officials and with health system representatives. Based on the research conducted within each work package, concrete recommendations for improved cervical cancer prevention will be developed and shared with health policy makers and other stakeholders. Since the PI is Director of Cancer Preventive service in Tanzania at ORCI and a member of the Ministry of Health technical working group for cervical cancer prevention and control in Tanzania, he will ensure the recommendations of the project are sent to the respective authorities and implemented. Initially most of the technical recommendations from the project will be implemented at ORCI, KCMC and among cervical cancer screening implementing partners in Tanzania after update of the cervical cancer screening national service delivery guidelines. Furthermore, through a phased and participatory approach, the policy recommendations for the Ministry of Health, will be discussed at the relevant level of authority in order to ensure the updated policy guidelines and ministerial circulars for cervical cancer include the project recommendations on improvement, particularly on continuity of care. The Tanzanian post-doctoral and PhD students will be in the forefront in the implementation and sustainability of the comprehensive cervical cancer prevention in Tanzania given the knowledge and skills obtained in the project; and it is anticipated that they will be employed by ORCI and KCMC or even at the Ministry of Health. The established cohort of HPV positive women will be kept and maintained at ORCI for future studies on HPV persistence and clearance patterns and women's absolute risk of subsequently developing precancerous lesions (17) . THE SCHEMATIC OVERVIEW OF THE PROJECT MILESTONES AND TIMETABLE   MILESTONES  2015  2016  2017  2018  2019   Work packages   Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3 Note: Project commencement involves planning meeting of researchers, setting up of the project office, and ensuring ethical clearance is obtained from relevant bodies Note: Project completion involves writing of the final project report, final auditing of the project, phasing out of the project to ensure sustainability
